Sugi Predict

Sugi Predict / Compounds / SCHEMBL126506

SCHEMBL126506

SCHEMBL126506

COCC(=O)CC(=O)OC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MGAM O43451 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ SI P14410 1/20 0.50
▸ MGAM2 Q2M2H8 1/20 0.50
▸ TSHR P16473 4/20 0.48
▸ HSD17B10 Q99714 2/20 0.43
▸ LMNA P02545 3/20 0.39
▸ KDM4E B2RXH2 1/20 0.39
▸ KMT2A Q03164 2/20 0.36
▸ TET2 Q6N021 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ CA12 O43570 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ RECQL P46063 1/20 0.34
▸ NPSR1 Q6W5P4 1/20 0.34
▸ ALDH1A1 P00352 3/20 0.33
▸ MAPT P10636 1/20 0.33
▸ HTT P42858 1/20 0.33
▸ POLB P06746 1/20 0.32
▸ POLA1 P09884 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16425793 0.85 TSHR (0.40) MGAMGAASIMGAM2TSHR
SCHEMBL27976 0.82 MGAM (0.61) MGAMGAASIMGAM2TSHR
SCHEMBL3545243 0.80 TSHR (0.59) MGAMGAASIMGAM2TSHR
SCHEMBL126088 0.80 GAA (0.61) MGAMGAASIMGAM2TSHR
SCHEMBL29374 0.79 — —
SCHEMBL15688315 0.79 MGAM (0.58) MGAMGAASIMGAM2TSHR
SCHEMBL2727988 0.79 TSHR (0.65) MGAMGAASIMGAM2TSHR
SCHEMBL128682 0.79 LMNA (0.39) GAATSHRHSD17B10LMNAKDM4E
SCHEMBL3821975 0.79 DGAT1 (0.40) MGAMGAASIMGAM2TSHR
SCHEMBL626926 0.78 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1030 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117466735-A Continuous preparation of methyl 4-methoxy acetoacetate 中化医药有限公司 2024-01-30 — — CN claimed
CN-114213249-B Synthesis method of dolutegravir intermediate 瑞孚信江苏药业股份有限公司 2023-09-01 — — CN claimed
CN-116496296-A Dolutegravir derivative with anti-tumor function and preparation method thereof 河南师范大学 2023-07-28 — — CN claimed
CN-116239470-A Preparation method of 4-methoxy methyl acetoacetate 中化医药有限公司 2023-06-09 — — CN claimed
CN-116063179-A Synthesis method of 4-methoxy methyl acetoacetate 南京杰运医药科技有限公司 2023-05-05 — — CN claimed
CN-116003435-A Efficient green preparation method of dolutegravir 河南师范大学 2023-04-25 — — CN claimed
CN-115746022-A Preparation method and application of caspovir derivative 河南科技大学 2023-03-07 — — CN claimed
CN-114605437-A Synthesis process for preparing three telaprevir medicaments by continuous one-pot method 遵义医科大学 2022-06-10 — — CN claimed
CN-113527334-B Triazole derivative capable of influencing calcium ion channel of tumor cell and preparation method and application thereof 济南爱思医药科技有限公司 2022-04-29 — — CN claimed
CN-112624923-B Preparation method of 4-methoxy methyl acetoacetate 盐城迪赛诺制药有限公司 2022-04-15 — — CN claimed
US-20200040108-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA 2020-02-06 — — US claimed
WO-2020026143-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) 2020-02-06 — — WO claimed
EP-3604346-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES Procter & Gamble International Operations SA (CH) 2020-02-05 — — EP claimed
US-20190106435-A1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES VIIV HEALTHCARE COMPANY 2019-04-11 — — US claimed
EP-3260457-A1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES VIIV Healthcare Company (US) 2017-12-27 — — EP claimed
EP-2549870-B1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES VIIV HEALTHCARE CO (US) 2017-04-19 — — EP claimed
US-20130172551-A1 Process for Preparing Carbamolypyridone Derivatives and Intermediates VIIV HEALTHCARE COMPANY 2013-07-04 — — US claimed
EP-2549870-A1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES VIIV Healthcare Company (US) 2013-01-30 — — EP claimed
WO-2011119566-A1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES GLAXOSMITHKLINE LLC (US) 2011-09-29 — — WO claimed
EP-0912467-B1 ASYMMETRIC HYDROGENATION METHOD OF A KETONIC COMPOUND AND DERIVATIVE RHODIA CHIMIE SA (FR) 2002-04-24 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190106435-A1 PROCESS FOR PREPARING CARBAMOYLPYRIDONE DERIVATIVES AND INTERMEDIATES CPS1, CYP3A4, SDHA MGAM 2239/4885GAA 1770/4885SI 1034/4885
US-20130172551-A1 Process for Preparing Carbamolypyridone Derivatives and Intermediates CPS1, CYP3A4, DHPS MGAM 2134/4885GAA 3024/4885SI 1679/4885
US-20200040108-A1 PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES MGAM, FUT5, FUT6 MGAM 1/4885GAA 341/4885SI 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.